GSK Begins Detailing Xenical Ahead Of OTC Switch Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's Consumer Healthcare division will detail the weight-loss therapy, focusing on diabetes risk reduction data recently added to labeling. Xenical was last detailed by Roche in November 2003. The Rx-to-OTC application is planned for mid-year.
You may also be interested in...
Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial
Tokyo-based Sosei Group is not ready to give up on its fibromyalgia candidate AD 337 after a Phase II study failed to meet its primary endpoint, the firm announced Sept. 18
Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial
Firm says drug could have some potential in treatment of fibromyalgia syndrome.
Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial
Firm says drug could have some potential in treatment of fibromyalgia syndrome.